Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01503866 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study to Investigate the Absorption, Metabolism and Excretion in Healthy Male Subjects
A Phase 1 study, sponsored by Biogen.
- Completed
- Registry status
- Phase 1
- Development phase
- 6
- Enrollment target
NCT01503866 is a Phase 1 study that has completed, run by Biogen. The registered enrollment target is 6 participants.
The verdict
NCT01503866, a Phase 1 study, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the absorption and excretion kinetics of bardoxolone methyl and to determine and characterize metabolites present in plasma, urine and feces in men following a single oral does or 20 mg of \[14C\]-bardoxolone methyl.
Interventions
- DRUG bardoxolone methyl
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2011-12-01 |
| Est. Completion | 2011-12-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01503866
The ClinicalTrials.gov registry entry for NCT01503866 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which bardoxolone methyl is the first listed.
NCT01503866 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01503866 about?
NCT01503866 is a clinical study titled "A Phase I Study to Investigate the Absorption, Metabolism and Excretion in Healthy Male Subjects". The purpose of this study is to determine the absorption and excretion kinetics of bardoxolone methyl and to determine and characterize metabolites present in plasma, urine and feces in men following a single oral does or 20 mg of \[14C\]-bardoxolone methyl.
What is the current status of trial NCT01503866?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 6 participants. The study started on 2011-12-01. Estimated completion is 2011-12-31.
What interventions are being tested in trial NCT01503866?
The interventions under investigation include: bardoxolone methyl (DRUG).
Who is sponsoring clinical trial NCT01503866?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.